Jefferies analyst, David Steinberg, reiterated Buy rating on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) but cut his price target to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE